vs
爱齐科技（ALGN）与Idexx Laboratories（IDXX）财务数据对比。点击上方公司名可切换其他公司
Idexx Laboratories的季度营收约是爱齐科技的1.0倍（$1.1B vs $1.0B），Idexx Laboratories净利率更高（22.8% vs 13.0%，领先9.8%），Idexx Laboratories同比增速更快（14.3% vs 5.3%），Idexx Laboratories自由现金流更多（$326.3M vs $187.3M），过去两年Idexx Laboratories的营收复合增速更高（6.4% vs 2.5%）
爱齐科技是一家全球知名医疗设备企业，主营设计、生产及销售隐适美透明矫治器、iTero口内扫描仪及配套服务，客户覆盖正畸医师、全科牙医，面向修复、美容牙科领域，业务分为透明矫治器、扫描仪及服务两大板块，可满足青少年等不同群体的正畸需求
IDEXX Laboratories是1983年成立的美国跨国企业，主营伴侣动物诊疗、畜禽养殖、水质检测、乳制品领域相关产品与服务的研发、生产及分销，总部位于缅因州韦斯特布鲁克，欧洲、中东及非洲地区分部设于荷兰霍夫多普。
ALGN vs IDXX — 直观对比
营收规模更大
IDXX
是对方的1.0倍
$1.0B
营收增速更快
IDXX
高出9.0%
5.3%
净利率更高
IDXX
高出9.8%
13.0%
自由现金流更多
IDXX
多$139.1M
$187.3M
两年增速更快
IDXX
近两年复合增速
2.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.1B |
| 净利润 | $135.8M | $248.2M |
| 毛利率 | 65.3% | 60.3% |
| 营业利润率 | 14.8% | 28.9% |
| 净利率 | 13.0% | 22.8% |
| 营收同比 | 5.3% | 14.3% |
| 净利润同比 | 30.8% | 14.8% |
| 每股收益（稀释后） | $1.88 | $3.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALGNIDXX
| Q4 25 | $1.0B | $1.1B | ||
| Q3 25 | $995.7M | $1.1B | ||
| Q2 25 | $1.0B | $1.1B | ||
| Q1 25 | $979.3M | $998.4M | ||
| Q4 24 | $995.2M | $954.3M | ||
| Q3 24 | $977.9M | $975.5M | ||
| Q2 24 | $1.0B | $1.0B | ||
| Q1 24 | $997.4M | $964.1M |
净利润ALGNIDXX
| Q4 25 | $135.8M | $248.2M | ||
| Q3 25 | $56.8M | $274.6M | ||
| Q2 25 | $124.6M | $294.0M | ||
| Q1 25 | $93.2M | $242.7M | ||
| Q4 24 | $103.8M | $216.1M | ||
| Q3 24 | $116.0M | $232.8M | ||
| Q2 24 | $96.6M | $203.3M | ||
| Q1 24 | $105.0M | $235.6M |
毛利率ALGNIDXX
| Q4 25 | 65.3% | 60.3% | ||
| Q3 25 | 64.2% | 61.8% | ||
| Q2 25 | 69.9% | 62.6% | ||
| Q1 25 | 69.5% | 62.4% | ||
| Q4 24 | 70.0% | 59.8% | ||
| Q3 24 | 69.7% | 61.1% | ||
| Q2 24 | 70.3% | 61.7% | ||
| Q1 24 | 70.0% | 61.5% |
营业利润率ALGNIDXX
| Q4 25 | 14.8% | 28.9% | ||
| Q3 25 | 9.7% | 32.1% | ||
| Q2 25 | 16.1% | 33.6% | ||
| Q1 25 | 13.4% | 31.7% | ||
| Q4 24 | 14.5% | 27.4% | ||
| Q3 24 | 16.6% | 31.2% | ||
| Q2 24 | 14.3% | 26.3% | ||
| Q1 24 | 15.5% | 31.0% |
净利率ALGNIDXX
| Q4 25 | 13.0% | 22.8% | ||
| Q3 25 | 5.7% | 24.8% | ||
| Q2 25 | 12.3% | 26.5% | ||
| Q1 25 | 9.5% | 24.3% | ||
| Q4 24 | 10.4% | 22.7% | ||
| Q3 24 | 11.9% | 23.9% | ||
| Q2 24 | 9.4% | 20.3% | ||
| Q1 24 | 10.5% | 24.4% |
每股收益（稀释后）ALGNIDXX
| Q4 25 | $1.88 | $3.09 | ||
| Q3 25 | $0.78 | $3.40 | ||
| Q2 25 | $1.72 | $3.63 | ||
| Q1 25 | $1.27 | $2.96 | ||
| Q4 24 | $1.40 | $2.62 | ||
| Q3 24 | $1.55 | $2.80 | ||
| Q2 24 | $1.28 | $2.44 | ||
| Q1 24 | $1.39 | $2.81 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $180.1M |
| 总债务越低越好 | — | $450.0M |
| 股东权益账面价值 | $4.0B | $1.6B |
| 总资产 | $6.2B | $3.4B |
| 负债/权益比越低杠杆越低 | — | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资ALGNIDXX
| Q4 25 | $1.1B | $180.1M | ||
| Q3 25 | $1.0B | $208.2M | ||
| Q2 25 | $901.2M | $164.6M | ||
| Q1 25 | $873.0M | $164.0M | ||
| Q4 24 | $1.0B | $288.3M | ||
| Q3 24 | $1.0B | $308.6M | ||
| Q2 24 | $761.4M | $401.6M | ||
| Q1 24 | $865.8M | $397.4M |
总债务ALGNIDXX
| Q4 25 | — | $450.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $617.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ALGNIDXX
| Q4 25 | $4.0B | $1.6B | ||
| Q3 25 | $4.0B | $1.6B | ||
| Q2 25 | $3.9B | $1.5B | ||
| Q1 25 | $3.8B | $1.4B | ||
| Q4 24 | $3.9B | $1.6B | ||
| Q3 24 | $3.9B | $1.6B | ||
| Q2 24 | $3.8B | $1.6B | ||
| Q1 24 | $3.8B | $1.6B |
总资产ALGNIDXX
| Q4 25 | $6.2B | $3.4B | ||
| Q3 25 | $6.2B | $3.4B | ||
| Q2 25 | $6.2B | $3.3B | ||
| Q1 25 | $6.1B | $3.2B | ||
| Q4 24 | $6.2B | $3.3B | ||
| Q3 24 | $6.4B | $3.4B | ||
| Q2 24 | $6.2B | $3.4B | ||
| Q1 24 | $6.2B | $3.4B |
负债/权益比ALGNIDXX
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.39× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $223.2M | $355.8M |
| 自由现金流经营现金流 - 资本支出 | $187.3M | $326.3M |
| 自由现金流率自由现金流/营收 | 17.9% | 29.9% |
| 资本支出强度资本支出/营收 | 3.4% | 2.7% |
| 现金转化率经营现金流/净利润 | 1.64× | 1.43× |
| 过去12个月自由现金流最近4个季度 | $490.8M | $1.1B |
8季度趋势，按日历期对齐
经营现金流ALGNIDXX
| Q4 25 | $223.2M | $355.8M | ||
| Q3 25 | $188.7M | $402.3M | ||
| Q2 25 | $128.7M | $185.7M | ||
| Q1 25 | $52.7M | $238.0M | ||
| Q4 24 | $286.1M | $262.0M | ||
| Q3 24 | $263.7M | $220.1M | ||
| Q2 24 | $159.8M | $248.3M | ||
| Q1 24 | $28.7M | $198.6M |
自由现金流ALGNIDXX
| Q4 25 | $187.3M | $326.3M | ||
| Q3 25 | $169.0M | $371.2M | ||
| Q2 25 | $107.2M | $151.6M | ||
| Q1 25 | $27.4M | $207.9M | ||
| Q4 24 | $263.1M | $232.8M | ||
| Q3 24 | $233.9M | $192.0M | ||
| Q2 24 | $106.4M | $215.0M | ||
| Q1 24 | $19.3M | $168.3M |
自由现金流率ALGNIDXX
| Q4 25 | 17.9% | 29.9% | ||
| Q3 25 | 17.0% | 33.6% | ||
| Q2 25 | 10.6% | 13.7% | ||
| Q1 25 | 2.8% | 20.8% | ||
| Q4 24 | 26.4% | 24.4% | ||
| Q3 24 | 23.9% | 19.7% | ||
| Q2 24 | 10.3% | 21.4% | ||
| Q1 24 | 1.9% | 17.5% |
资本支出强度ALGNIDXX
| Q4 25 | 3.4% | 2.7% | ||
| Q3 25 | 2.0% | 2.8% | ||
| Q2 25 | 2.1% | 3.1% | ||
| Q1 25 | 2.6% | 3.0% | ||
| Q4 24 | 2.3% | 3.1% | ||
| Q3 24 | 3.0% | 2.9% | ||
| Q2 24 | 5.2% | 3.3% | ||
| Q1 24 | 0.9% | 3.1% |
现金转化率ALGNIDXX
| Q4 25 | 1.64× | 1.43× | ||
| Q3 25 | 3.33× | 1.47× | ||
| Q2 25 | 1.03× | 0.63× | ||
| Q1 25 | 0.57× | 0.98× | ||
| Q4 24 | 2.76× | 1.21× | ||
| Q3 24 | 2.27× | 0.95× | ||
| Q2 24 | 1.66× | 1.22× | ||
| Q1 24 | 0.27× | 0.84× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALGN
| Systems And Services | $789.6M | 75% |
| Other | $258.0M | 25% |
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
